Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Persistent Asset Partners Ltd

Persistent Asset Partners Ltd grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 428.0% during the third quarter, Holdings Channel reports. The firm owned 6,911 shares of the biopharmaceutical company’s stock after acquiring an additional 5,602 shares during the quarter. Regeneron Pharmaceuticals comprises 2.7% of Persistent Asset Partners Ltd’s portfolio, making the stock its 5th largest holding. Persistent Asset Partners Ltd’s holdings in Regeneron Pharmaceuticals were worth $3,886,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Salomon & Ludwin LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Regeneron Pharmaceuticals in the second quarter valued at approximately $31,000. Traub Capital Management LLC bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $38,000. Berbice Capital Management LLC raised its position in shares of Regeneron Pharmaceuticals by 300.0% during the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 60 shares during the period. Finally, E Fund Management Hong Kong Co. Ltd. lifted its holdings in shares of Regeneron Pharmaceuticals by 87.5% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 35 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, SVP Jason Pitofsky sold 2,036 shares of the firm’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the transaction, the senior vice president owned 4,272 shares in the company, valued at approximately $3,325,837.44. This trade represents a 32.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Bonnie L. Bassler sold 1,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the sale, the director owned 1,703 shares in the company, valued at $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 3,636 shares of company stock worth $2,862,920. 7.02% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on REGN. Oppenheimer restated an “outperform” rating and set a $865.00 price objective (up from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, February 2nd. Cantor Fitzgerald upped their price target on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a research report on Monday, February 2nd. Evercore increased their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a report on Thursday, January 22nd. UBS Group boosted their target price on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a research note on Friday, November 7th. Finally, JPMorgan Chase & Co. upped their target price on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a research report on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $793.81.

Regeneron Pharmaceuticals Stock Down 1.2%

Regeneron Pharmaceuticals stock opened at $782.38 on Friday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11. The stock has a market cap of $82.71 billion, a price-to-earnings ratio of 18.83, a PEG ratio of 2.13 and a beta of 0.40. The company’s 50-day moving average price is $768.21 and its two-hundred day moving average price is $671.68. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same period last year, the firm posted $12.07 earnings per share. The business’s revenue was up 2.5% on a year-over-year basis. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 5th. Investors of record on Friday, February 20th will be issued a dividend of $0.94 per share. The ex-dividend date of this dividend is Friday, February 20th. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.47%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.